Page 2 - Ecdna News Today

Shares of CareDx, Inc (NASDAQ:CDNA – Get Free Report) have been assigned a consensus rating of “Hold” from the six ratings firms that are covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price […]

CareDx, Inc (NASDAQ:CDNA – Get Free Report) has received an average rating of “Hold” from the six ratings firms that are covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12-month target price among brokers that have […]

CareDx, Inc (NASDAQ:CDNA – Get Free Report) was the target of a large decline in short interest in the month of September. As of September 30th, there was short interest totalling 3,500,000 shares, a decline of 10.3% from the September 15th total of 3,900,000 shares. Based on an average daily volume of 742,300 shares, the […]

Cancer treatments for targeting tumor amplifications lag behind those targeting point mutations – and part of the reason may be that amplifications often reside on extrachromosomal DNA (ecDNA). Since ecDNA was first described back in 1965 as minute chromatin bodies in brain cancer cells, the use of large-scale DNA sequencing techniques has revealed the presence of ecDNA across a wide range of cancer types. “The circular structure of ecDNA is associated with increased proto-oncogenic capacity...

StockNews.com started coverage on shares of CareDx (NASDAQ:CDNA – Free Report) in a research report sent to investors on Thursday. The firm issued a hold rating on the stock. A number of other analysts have also weighed in on the stock. HC Wainwright reiterated a neutral rating on shares of CareDx in a report on […]

CareDx, Inc (NASDAQ:CDNA – Get Free Report) has been assigned an average rating of “Hold” from the six ratings firms that are currently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month target price among […]

Shares of CareDx, Inc (NASDAQ:CDNA – Get Free Report) have been assigned a consensus recommendation of “Hold” from the six research firms that are currently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12-month price […]

CareDx (NASDAQ:CDNA – Get Free Report) and Aclarion (NASDAQ:ACON – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk. Earnings and Valuation This table compares CareDx and Aclarion’s […]

Royce & Associates LP raised its holdings in CareDx, Inc (NASDAQ:CDNA – Free Report) by 332.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 432,505 shares of the company’s stock after purchasing an additional 332,400 shares during the quarter. Royce & Associates LP’s […]

StockNews.com started coverage on shares of CareDx (NASDAQ:CDNA – Free Report) in a research report sent to investors on Thursday. The brokerage issued a hold rating on the stock. A number of other analysts also recently issued reports on CDNA. BTIG Research downgraded shares of CareDx from a buy rating to a neutral rating in […]